Tag: prostate cancer

UPDATE: 10/26/2021 Originally published 7/7/2018 Dr. Snuffy Myers may be the world’s champion at durable remission of the prostate cancer (PCa). As a now-retired oncologist and survivor of the disease, he continues to lead, inspire and inform PCa patients. This update emphasizes Key Lifestyle Factor #4 in the original blog, Healthy Diet, based on a keep reading

Rising healthcare costs are even more concerning today than in 2014, when we posted the blog below. At the same time, advances in medical technology have continued at a steady pace. This is especially true for the ever-increasing applications of multiparametric MRI (mpMRI) in prostate cancer detection, diagnosis and treatment. keep reading

I have never met Dr. Bert Vorstman, a urologist in Coral Springs, FL, but he sounds like a doctor who is not afraid to speak his mind. In fact, he calls robotic prostate cancer surgery “a public health nightmare” and a “boondoggle for public health.” These are strong words, especially coming from a surgically-trained urologist... keep reading

Fourteen months prior to the time of this writing, the world began locking down due to the emerging SARS-CoV-2 viral pandemic and the potentially deadly COVID illness it causes. We were all confused, and studies repeatedly show that normal screening for cancers such as breast, prostate and colorectal dropped significantly... keep reading

Over the years, I have spoken with many patients about the idea of doctors being 100% open with regard to their treatment results. I came across a large-scaled Swedish study on prostatectomy side effects, and it’s as transparent as it gets. keep reading

Everyone has heard the term “chemotherapy” and it conjures up scary, negative images. On the other hand, have you heard the term “chemoprevention”? The National Cancer Institute defines chemoprevention as “the use of pharmacologic or natural agents that inhibit the development of invasive cancer... keep reading

Just under six months ago, the FDA approved the first radiopharmaceutical, Gallium-68 PSMA-11, for prostate cancer (PCa) detection by PET-CT scans. Approval meant that this injectable isotope had achieved special status as “a first”. The FDA granted its approval for two purposes: (a) Suspicion of PCa recurrence after treatment, and (b)Suspicion of metastasis (spread) at keep reading

Beyond doubt, PSA screening for prostate cancer (PCa) has saved hundreds of thousands of lives since the blood test was introduced in the mid-1990s. However, the classical screening strategy involved a pathway from a suspiciously high or rising PSA directly to... keep reading

In 2014, the International Society of Urological Pathology released a proposed new prostate cancer grading system, called the Grade Groups (GG). Our initial post explains some of the reasoning behind simplifying the traditional Gleason scoring system into a more understandable 5-point aggression scale... keep reading

In 2009, Gat et al.[iv] published a paper that should have made a much bigger splash than it did. They accounted for the origin of two major prostate problems with one simple explanation: blood “backing up” into the prostate from the testicles. keep reading